Finally, therapeutic CSPG4-directed cancer cell death may also be achieved using a bsAb-based approach as is exemplified by bsAb MCSPxDR5 that can exert strong and selective DR5-dependent cytotoxic activity against CSPG4-expressing melanoma cells. Here, CSPG4 is linked to cancer.